Clear Street downgrades Janux Therapeutics (JANX) to Hold, slashing its price target amid concerns over a lack of durability data for its lead candidate JANX007 and rising competitive pressures, despite a recent major collaboration deal with Bristol Myers Squibb.
Following a price target adjustment by Leerink Partners, Kura Oncology (KURA) is drawing investor focus to its 2026 clinical milestones and commercial strategy for its newly launched AML drug, ziftomenib.
The Apis Flagship Fund reported robust quarterly and annual gains for 2025, significantly beating global benchmarks. While highlighting its performance drivers, the fund's investor letter also discussed its position on gene therapy firm uniQure (QURE).
The White House has confirmed the launch of a major strategic initiative to stockpile rare earth elements, aiming to reduce American dependence on China for the critical minerals used in defense tech and consumer electronics.
Apis Capital's flagship fund, which surged 55% in 2025, spotlights clinical-stage biotech Celcuity in its latest investor letter, citing the company's novel platform for matching cancer patients with targeted therapies.
Analysts at Stifel have raised their price target for Nurix Therapeutics (NRIX) to $35, maintaining a Buy rating ahead of anticipated 2026 clinical milestones for its lead asset, bexobrutinib. The move comes as Wells Fargo also adjusted its target, highlighting divergent near-term views but shared long-term optimism for the biotech firm.
Amphenol Corporation (NYSE: APH), a key player in electronic connectors, received concurrent price target increases from Seaport Research and Citi. While analysts highlight growth potential, the stock's post-earnings dip underscores a cautious market stance toward the company's traditionally conservative guidance.
The renewable energy firm's latest quarterly results, described as a 'beat and raise,' have prompted major banks to lift their valuations, signaling strong confidence in its growth trajectory within the clean energy sector.
U.S. stock futures point lower amid renewed scrutiny over AI investments, with Nvidia's landmark OpenAI deal reportedly under strain. Disney beats earnings estimates as leadership transition talks emerge, while Oracle plans a massive $50 billion raise to fuel its AI ambitions.
Ford Motor Company launches a dedicated energy storage business, Ford Energy, appointing Lisa Drake to lead the charge into the rapidly growing battery storage market, signaling a strategic expansion beyond vehicle manufacturing.
Edwards Lifesciences (NYSE: EW) has terminated its planned takeover of JenaValve, opting instead to reinvest capital into its internal transcatheter aortic (TAVR) and mitral valve development programs. The strategic pivot underscores a renewed focus on organic growth in its core structural heart business.
Caterpillar Inc. (CAT) reported stronger-than-expected fourth-quarter results, driven largely by surging demand for power generation equipment from the artificial intelligence data center sector, offsetting softer performance in its traditional construction and mining divisions.
While the Schwab U.S. Dividend Equity ETF (SCHD) remains a cornerstone for income investors, a new analysis highlights several compelling alternatives that address its potential gaps in sector exposure, yield, and international diversification.
During UK Foreign Secretary Yvette Cooper's visit to Addis Ababa, British investor Gridworks signed landmark agreements to develop two major transmission projects. The deals, part of a broader UK strategy linking economic development with migration management, mark Ethiopia's first public-private partnerships in its power transmission sector.
Israeli police have detained municipal officials and business figures suspected of embezzling millions in international donations intended for communities devastated by the October 7 Hamas attacks, launching a major fraud investigation.
In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.
Investment firm Curreen Capital, known for targeting undervalued 'ugly duckling' companies, highlighted contract research organization Fortrea Holdings as a prime example of its strategy in its latest investor letter. The firm reported a 30.97% return for 2025.
Tesla shares have surged nearly 40% in six months, driven by robotaxi and Optimus robot prospects. Now, swirling rumors of a potential merger with Elon Musk's SpaceX are adding rocket fuel to investor optimism, though analysts urge caution amid sky-high valuations.
U.S. stocks and precious metals fell sharply Monday as President Trump's surprise nomination of Kevin Warsh to lead the Federal Reserve injected fresh uncertainty into markets, reversing a recent dollar slump and cooling a historic gold rally.
In a cafe in eastern Turkey, Iranian exiles gather, their eyes fixed on news from home. As a new wave of protests meets a severe crackdown, those who fled earlier unrest watch, wait, and voice a desperate mix of anguish, anger, and fragile hope.
